GLP-1 peptide increases and decreases insulin and glucagon secretion, respectively, and modulates blood glucose levels and also one of the therapeutic targets for type 2 diabetes mellitus are GLP-1RAs (GLP-1 receptor agonists) (82). Here, INS is linked to type 2 diabetes mellitus.